BIO CEO defends the organization's about-face on the Biosecure Act
As the head of the trade group BIO and a parent to children with a rare disease, John Crowley is personally and professionally at the center of a bill targeting Chinese biotechs.
Under Crowley, BIO switched its stance to support the proposed Biosecure Act that would essentially ban WuXi AppTec and other contractors that are ubiquitous in drug development. But among the companies that have flagged supply chain risks from the legislation is Amicus Therapeutics, a company founded by Crowley that developed a rare disease medicine for his two children and others with Pompe disease.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
